期刊
PEDIATRIC RESEARCH
卷 66, 期 5, 页码 577-584出版社
NATURE PUBLISHING GROUP
DOI: 10.1203/PDR.0b013e3181baa3c2
关键词
-
类别
资金
- Ministry of Education, Culture. Sports, Science and Technology [9022950]
- Kitasato University School of Medicine
- Morinaga Foundation for Health and Nutrition
- Kawasaki Disease Research Center in Japan
Intravenous immunoglobulin (IVIG) treatment-resistant patients are high risk of developing coronary artery lesions with Kawasaki disease. The IVIG-responsive (Group A; n = 6) and IVIG-resistant patients (Group B) were predicted before starting the initial treatment using the Egami scoring system and randomly allocated as a single-IVIG treatment group (group B 1; n = 6) or as a IVIG-plus-methylprednisolone (IVMP) combined therapy group (group B2; n = 5). We investigated the transcript abundance in the leukocytes of those patients using a microarray analysis. Five patients in group A and one patient in group B I responded to initial IVIG treatment. All group B2 patients responded to IVIG-plus-IVMP combined therapy. Before performing these treatments, those transcripts related to IVIG resistance and to the development of coronary artery lesions, such as IL1R, IL18R, oncostatin M, suppressor of cytokine signaling-3, S100A12 protein, carcinoembryonic antigen-related cell adhesion molecule-1, matrix metallopeptidase-9, and polycythemia rubra vera-1, were more abundant in group B patients in comparison with group A patients. Moreover, those transcripts in group B2 patients were more profoundly and broadly suppressed than group B I patients after treatment. This study. elucidated the molecular mechanism of the effectiveness of IVIG-plus-IVMP combined therapy. (Pediatr Res 66: 577-584, 2009)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据